ALLO
Allogene Therapeutics, Inc.
Key Financials
Revenue
$0
↓ 100.0%
Operating Income
$-209315000
↑ 23.4%
Net Income
$-190886000
↑ 25.9%
Total Assets
$415.9M
↓ 24.2%
EPS (Diluted)
$-0.87
↑ 34.1%
Total Liabilities
$123.4M
↓ 2.5%
Shareholders' Equity
$292.5M
↓ 30.7%
Cash & Equivalents
$51.7M
↓ 31.3%
Recent SEC Filings
| Form Type | Filed Date | Link |
|---|---|---|
| SCHEDULE 13G/A | 5/15/2026 | View on SEC |
| SCHEDULE 13G/A | 5/15/2026 | View on SEC |
| SCHEDULE 13G/A | 5/13/2026 | View on SEC |
| SCHEDULE 13G/A | 5/13/2026 | View on SEC |
| 10-Q | 5/13/2026 | View on SEC |
| 8-K | 5/13/2026 | View on SEC |
| ARS | 4/30/2026 | View on SEC |
| DEFA14A | 4/30/2026 | View on SEC |
| DEF 14A | 4/30/2026 | View on SEC |
| SCHEDULE 13G | 4/23/2026 | View on SEC |
Company Information
| Field | Value |
|---|---|
| Ticker | ALLO |
| Company Name | Allogene Therapeutics, Inc. |
| CIK | 1737287 |
| Sector | Biological Products, (No Diagnostic Substances) |
| Industry | Non-accelerated filer Smaller reporting company |
| Exchange | Nasdaq |
| SIC Code | 2836 |
| SIC Description | Biological Products, (No Diagnostic Substances) |
| Entity Type | operating |
| Fiscal Year End | 1231 |
| Phone | (650) 457-2700 |